TSE:WEED

Canopy Growth Competitors

C$29.23
-1.45 (-4.73 %)
(As of 05/10/2021 02:21 PM ET)
Add
Compare
Today's Range
C$29.18
C$30.61
50-Day Range
C$29.64
C$43.00
52-Week Range
C$18.34
C$71.60
Volume872,403 shs
Average Volume1.51 million shs
Market CapitalizationC$11.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Canopy Growth (TSE:WEED) Vs. LEAF, OGI, EMC, ICC, CMED, and MJN

Should you be buying WEED stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Canopy Growth, including Leaf Mobile (LEAF), OrganiGram (OGI), Emblem (EMC), ICC Labs (ICC), (CMED.TO) (CMED), and (MJN.V) (MJN).

Leaf Mobile (TSE:LEAF) and Canopy Growth (TSE:WEED) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Valuation & Earnings

This table compares Leaf Mobile and Canopy Growth's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leaf MobileC$31.09 million10.20C$-17,580,671.00C($0.02)-18.04
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55

Leaf Mobile has higher earnings, but lower revenue than Canopy Growth. Leaf Mobile is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Leaf Mobile and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Leaf MobileN/AN/AN/A
Canopy GrowthN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and price targets for Leaf Mobile and Canopy Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Leaf Mobile00203.00
Canopy Growth44001.50

Leaf Mobile currently has a consensus price target of C$0.88, indicating a potential upside of 108.33%. Canopy Growth has a consensus price target of C$38.46, indicating a potential upside of 30.47%. Given Leaf Mobile's stronger consensus rating and higher probable upside, research analysts plainly believe Leaf Mobile is more favorable than Canopy Growth.

Summary

Leaf Mobile beats Canopy Growth on 5 of the 8 factors compared between the two stocks.

Canopy Growth (TSE:WEED) and OrganiGram (TSE:OGI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares Canopy Growth and OrganiGram's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55
OrganiGramC$72.40 million12.89C$-340,283,853.00C($1.14)-2.74

OrganiGram has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than OrganiGram, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Canopy Growth and OrganiGram, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth44001.50
OrganiGram42201.75

Canopy Growth presently has a consensus price target of C$38.46, indicating a potential upside of 30.47%. OrganiGram has a consensus price target of C$3.78, indicating a potential upside of 19.53%. Given Canopy Growth's higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than OrganiGram.

Profitability

This table compares Canopy Growth and OrganiGram's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy GrowthN/AN/AN/A
OrganiGramN/AN/AN/A

Summary

OrganiGram beats Canopy Growth on 5 of the 8 factors compared between the two stocks.

Emblem (CVE:EMC) and Canopy Growth (TSE:WEED) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Emblem and Canopy Growth's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55

Emblem has higher earnings, but lower revenue than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Emblem and Canopy Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
Canopy Growth44001.50

Canopy Growth has a consensus target price of C$38.46, indicating a potential upside of 30.47%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than Emblem.

Profitability

This table compares Emblem and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
Canopy GrowthN/AN/AN/A

Canopy Growth (TSE:WEED) and ICC Labs (CVE:ICC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Canopy Growth and ICC Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy GrowthN/AN/AN/A
ICC LabsN/AN/AN/A

Valuation & Earnings

This table compares Canopy Growth and ICC Labs' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55
ICC LabsC$533,684.00419.04C$2.35 millionC$0.0295.29

ICC Labs has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Canopy Growth and ICC Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth44001.50
ICC Labs0000N/A

Canopy Growth presently has a consensus target price of C$38.46, indicating a potential upside of 30.47%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than ICC Labs.

Summary

ICC Labs beats Canopy Growth on 4 of the 6 factors compared between the two stocks.

(CMED.TO) (TSE:CMED) and Canopy Growth (TSE:WEED) are both companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares (CMED.TO) and Canopy Growth's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CMED.TO)N/AN/AN/AN/AN/A
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55

(CMED.TO) has higher earnings, but lower revenue than Canopy Growth.

Profitability

This table compares (CMED.TO) and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CMED.TO)N/AN/AN/A
Canopy GrowthN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for (CMED.TO) and Canopy Growth, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CMED.TO)0000N/A
Canopy Growth44001.50

Canopy Growth has a consensus target price of C$38.46, suggesting a potential upside of 30.47%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than (CMED.TO).

Summary

Canopy Growth beats (CMED.TO) on 2 of the 2 factors compared between the two stocks.

Canopy Growth (TSE:WEED) and (MJN.V) (CVE:MJN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares Canopy Growth and (MJN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy GrowthN/AN/AN/A
(MJN.V)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Canopy Growth and (MJN.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth44001.50
(MJN.V)0000N/A

Canopy Growth currently has a consensus target price of C$38.46, indicating a potential upside of 30.47%. Given Canopy Growth's higher possible upside, research analysts plainly believe Canopy Growth is more favorable than (MJN.V).

Earnings & Valuation

This table compares Canopy Growth and (MJN.V)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy GrowthC$506.12 million22.10C$-2,459,879,050.00C($6.43)-4.55
(MJN.V)N/AN/AN/AN/AN/A

(MJN.V) has lower revenue, but higher earnings than Canopy Growth.

Summary

Canopy Growth beats (MJN.V) on 2 of the 2 factors compared between the two stocks.

Ad JuniorStocks
The next big gold stock could be on the horizon
See what exciting new gold opportunity, backed by legendary investor Eric Sprott, has geologist and author Byron King so excited.

Canopy Growth Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Leaf Mobile logo
LEAF
Leaf Mobile
1.2$0.42-3.6%C$2.47 billionC$31.09 million-18.04
OrganiGram logo
OGI
OrganiGram
1.2$3.13-7.0%C$999.08 millionC$72.40 million-2.74
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
ICC
ICC Labs
0.5$1.62-6.2%C$228.24 millionC$533,684.0095.29Gap Up
CMED
(CMED.TO)
0.6$27.00-5.6%C$0.00N/A0.00News Coverage
MJN
(MJN.V)
0.5$12.15-1.9%C$0.00N/A0.00
SL
(SL)
0.6N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BE
Beleave
0.6N/AN/AC$0.00N/A0.00High Trading Volume
BE
Beleave
0.6N/AN/A$0.00N/A0.00High Trading Volume
BLO
Cannabix Technologies
0.5N/AN/AC$0.00N/A0.00Gap Down
MGW
Maple Leaf Green World
0.6$0.79-88.6%C$0.00N/A0.00Gap Up
This page was last updated on 5/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.